Interventions for Youth at Risk of Bipolar Disorder

Current Treatment Options in Psychiatry

Volumn 1, Issue 1, 2014, Pages 37-47

  Duffy, Anne ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Adolescent; Antidepressants; Antioxidants; Bipolar disorder; Clinical staging; Early intervention; High risk; Lithium; Mood disorders; Mood stabilizers; Novel treatment; Nutraceuticals; Prevention; Treatment

Indexed keywords

EID: 84921746465     PISSN: None     EISSN: 21963061     Source Type: Journal    
DOI: 10.1007/s40501-013-0006-x     Document Type: Review

References (81)

1. McGorry PD, Nelson B, Goldstone S, Yung AR. Clinical staging: a heuristic and practical strategy for new research and better health and social outcomes for psychotic and related mood disorders. Can J Psychiatr Rev Can Psychiatr. 2010;55(8):486–97. This is a comprehensive review of key findings supporting that clinical staging is an important framework to refine mood and psychotic disorders and includes a discussion of the advantages of this diagnostic approach.
2. Pfaffenseller B, Fries GR, Wollenhaupt-Aguiar B, Colpo GD, Stertz L, Panizzutti B, et al. Neurotrophins, inflammation and oxidative stress as illness activity biomarkers in bipolar disorder. Expert Rev Neurother. 2013;13(7):827–42. This is a current concise overview of key candidate biomarkers related to bipolar disorder.
3. Grof P, Alda M, Ahrens B. Clinical course of affective disorders: were Emil Kraepelin and Jules Angst wrong? Psychopathology. 1995;28 Suppl 1:73–80. This paper provides a cogent discussion as to how the diagnosis of Bipolar Disorder has changed over recent history and highlights the implications for treatment response and clinical course and prognosis.
4. Leboyer M, Henry C, Paillere-Martinot ML, Bellivier F. Age at onset in bipolar affective disorders: a review. Bipolar Disord. 2005;7(2):111–8.
5. Duffy A, Alda M, Hajek T, Grof P. Early course of bipolar disorder in high-risk offspring: prospective study. Br J Psychiatry: J Ment Sci. 2009;195(5):457–8.
6. Angst J, Gamma A, Neuenschwander M, Ajdacic-Gross V, Eich D, Rossler W, et al. Prevalence of mental disorders in the Zurich Cohort Study: a twenty year prospective study. Epidemiol Psichiatr Soc. 2005;14(2):68–76.
7. Gottesman II, Laursen TM, Bertelsen A, Mortensen PB. Severe mental disorders in offspring with 2 psychiatrically ill parents. Arch Gen Psychiatry. 2010;67(3):252–7. This paper describes a large population-based study from Denmark showing the risk to age 52 in offspring with either no affected, 1 affected or 2 affected parents with either bipolar disorder or schizophrenia. It demonstrates that bipolar disorder risk is very much determined by a positive family history and that the illness starts to manifest during adolescence. It also demonstrates the importance of taking into account the major depression as part of the bipolar phenotype in at-risk youth.
8. Angst J, Sellaro R. Historical perspectives and natural history of bipolar disorder. Biol Psychiatry. 2000;48(6):445–57.
9. Trede KS, P.; Baethge, C.; Gerhard, A.; Maggini, C; Baldessarini, R.J. Manic-Depressive Illness: evolution in Kraepelin's Textbook, 1883–1926. Harv Rev Psychiatry. 2005(May/June):155–78.This is a very thorough and fasincating historical account of the development of Kraepelin's observations and how these shaped his thinking of the natural history of psychiatric illness and the basis upon which he drew categorical divisions.
10. Muller-Oerlinghausen B, Felber W, Berghofer A, Lauterbach E, Ahrens B. The impact of lithium long-term medication on suicidal behavior and mortality of bipolar patients. Arch Suicide Res. 2005;9(3):307–19.
11. Baethge C, Cassidy F. Fighting on the side of life: a special issue on suicide in bipolar disorder. Bipolar Disord. 2013;15(5):453–6.
12. Baethge C, Baldessarini RJ, Khalsa HM, Hennen J, Salvatore P, Tohen M. Substance abuse in first-episode bipolar I disorder: indications for early intervention. Am J Psychiatry. 2005;162(5):1008–10.
13. Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev. 2011;35(3):804–17. This paper summarizes the evidence regarding promising neurobiological pathways related to established illness progression and burden of illness in patients with bipolar disorder. The paper focuses on end-stage broadly defined bipolar disorder and highlights the need for such studies in high-risk youth in order to identify primary disease markers and separate these from burden of illness effects.
14. Grof P, Muller-Oerlinghausen B. A critical appraisal of lithium's efficacy and effectiveness: the last 60 years. Bipolar Disord. 2009;11 Suppl 2:10–9. This is a very concise comprehensive review of the evidence supporting the clinical effectiveness of lithium in various patient populations from the two authors with collectively the most experience using and studing lithium in the world today.
15. Duffy A, Grof P. Psychiatric diagnoses in the context of genetic studies of bipolar disorder. Bipolar Disord. 2001;3(6):270–5.
16. Kapczinski F, Vieta E, Andreazza AC, Frey BN, Gomes FA, Tramontina J, et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci Biobehav Rev. 2008;32(4):675–92.
17. Garnham J, Munro A, Slaney C, Macdougall M, Passmore M, Duffy A, et al. Prophylactic treatment response in bipolar disorder: results of a naturalistic observation study. J Affect Disord. 2007;104(1–3):185–90.
18. Grof P. Sixty years of lithium responders. Neuropsychobiology. 2010;62(1):8–16. A very good comprehensive review of a lifetime of work and learning from patients whose lives have been changed through effective treatment with lithium. This is a must read for any professional working with patients who warrant a trial of lithium treatment.
19. Duffy A, Grof P, Robertson C, Alda M. The implications of genetics studies of major mood disorders for clinical practice. J Clin Psychiatry. 2000;61(9):630–7.
20. Duffy A, Alda M, Milin R, Grof P. A consecutive series of treated affected offspring of parents with bipolar disorder: is response associated with the clinical profile? Can J Psychiatr Rev Can Psychiatr. 2007;52(6):369–76.
21. Duffy A, Milin R, Grof P. Maintenance treatment of adolescent bipolar disorder: open study of the effectiveness and tolerability of quetiapine. BMC Psychiatry. 2009;9:4.
22. DA Grof P, Cavazzoni P, et al. Is response to prophylactic lithium a familial trait? J Clin Psychiatry. 2002;63:942–7.
23. McGuffin P, Perroud N, Uher R, Butler A, Aitchison KJ, Craig I, et al. The genetics of affective disorder and suicide. Eur Psychiatry. 2010;25(5):275–7. A comprehensive overview of the key findings in genetic studies related to bipolar disorder and suicide.
24. Bienvenu OJ, Davydow DS, Kendler KS. Psychiatric 'diseases' versus behavioral disorders and degree of genetic influence. Psychol Med. 2011;41(1):33–40.
25. DelBello MP, Geller B. Review of studies of child and adolescent offspring of bipolar parents. Bipolar Disord. 2001;3(6):325–34.
26. Duffy A. The early natural history of bipolar disorder: what we have learned from longitudinal high-risk research. Can J Psychiatr. 2010;55(8):477–85. A comprehensive overview of the key findings and resolved controversies in the pediatric mania debate on the basis of complementary evidence from longitudinal high-risk studies.
27. Mesman E, Nolen WA, Reichart CG, Wals M, Hillegers MH. The Dutch bipolar offspring study: 12-year follow-up. Am J Psychiatry. 2013;170(5):542–9.
28. Duffy A, Horrocks J, Doucette S, Keown-Stoneman C, McCloskey S, Grof P. Childhood anxiety: an early predictor of mood disorders in offspring of bipolar parents. J Affect Disord. 2013;150(2):363–9.
29. Nurnberger JIJ, McInnis M, Reich W, Kastelic E, Wilcox HC, Glowinski A, et al. A high-risk study of bipolar disorder. Childhood clinical phenotypes as precursors of major mood disorders. Arch Gen Psychiatry. 2011;68(10):1012–20.
30. Duffy A, Horrocks J, Doucette S, Keown-Stoneman C, McCloskey S, Grof P. The developmental trajectory of bipolar disorder. Br J Psychiatry: J Ment Sci. 2013. Summarizes findings in support of a clinical staging model describing the early natural history of bipolar disorder as it develops in high-risk children and adolescents.
31. Duffy A. The nature of the association between childhood ADHD and the development of bipolar disorder: a review of prospective high-risk studies. Am J Psychiatry. 2012;169(12):1247–55.
32. Hillegers MH, Reichart CG, Wals M, Verhulst FC, Ormel J, Nolen WA. Five-year prospective outcome of psychopathology in the adolescent offspring of bipolar parents. Bipolar Disord. 2005;7(4):344–50.
33. Reichart CG, Nolen WA. Earlier onset of bipolar disorder in children by antidepressants or stimulants? An hypothesis. J Affect Disord. 2004;78(1):81–4.
34. DelBello MP, Soutullo CA, Hendricks W, Niemeier RT, McElroy SL, Strakowski SM. Prior stimulant treatment in adolescents with bipolar disorder: association with age at onset. Bipolar Disord. 2001;3(2):53–7.
35. Blacker D, Lavori PW, Faraone SV, Tsuang MT. Unipolar relatives in bipolar pedigrees: a search for indicators of underlying bipolarity. Am J Med Genet. 1993;48(4):192–9.
36. Winokur G, Tsuang MT, Crowe RR. The Iowa 500: affective disorder in relatives of manic and depressed patients. Am J Psychiatry. 1982;139(2):209–12.
37. Duffy A, Alda M, Hajek T, Sherry SB, Grof P. Early stages in the development of bipolar disorder. J Affect Disord. 2010;121(1–2):127–35.
38. Duffy A, Horrocks J, Milin R, Doucette S, Persson G, Grof P. Adolescent substance use disorder during the early stages of bipolar disorder: a prospective high-risk study. J Affect Disord. 2012;142(1–3):57–64.
39. Baethge C, Hennen J, Khalsa HM, Salvatore P, Tohen M, Baldessarini RJ. Sequencing of substance use and affective morbidity in 166 first-episode bipolar I disorder patients. Bipolar Disord. 2008;10(6):738–41.
40. McGorry PD NB, Amminger GP, et al. Intervention in individuals at ultra high risk for psychosis: a review and future directions. J Clin Psychiatry. 2009.
41. Conus P, McGorry PD. First-episode mania: a neglected priority for early intervention. Aust NZ J Psychiatry. 2002;36(2):158–72.
42. Scott J, Leboyer M, Hickie I, Berk M, Kapczinski F, Frank E, et al. Clinical staging in psychiatry: a cross-cutting model of diagnosis with heuristic and practical value. Br J Psychiatry: J Ment Sci. 2013;202(4):243–5.
43. Watkins ER, Mullan E, Wingrove J, Rimes K, Steiner H, Bathurst N, et al. Rumination-focused cognitive-behavioural therapy for residual depression: phase II randomised controlled trial. Br J Psychiatry: J Ment Sci. 2011;199(4):317–22.
44. Scott J. Psychotherapy for bipolar disorders - efficacy and effectiveness. J Psychopharmacol. 2006;20(2 Suppl):46–50.
45. Miklowitz DJ. Functional impairment, stress, and psychosocial intervention in bipolar disorder. Curr Psychiatry Rep. 2011;13(6):504–12.
46. Miklowitz DJ, Schneck CD, Singh MK, Taylor DO, George EL, Cosgrove VE, et al. Early intervention for symptomatic youth at risk for bipolar disorder: a randomized trial of family-focused therapy. J Am Acad Child Adolesc Psychiatry. 2013;52(2):121–31.
47. Miklowitz DJ, Chang KD, Taylor DO, George EL, Singh MK, Schneck CD, et al. Early psychosocial intervention for youth at risk for bipolar I or II disorder: a one-year treatment development trial. Bipolar Disord. 2011;13(1):67–75.
48. Berk M, Conus P, Kapczinski F, Andreazza AC, Yucel M, Wood SJ, et al. From neuroprogression to neuroprotection: implications for clinical care. Med J Aust. 2010;193(4 Suppl):S36–40.
49. Raison CL, Miller AH. Is depression an inflammatory disorder? Curr Psychiatry Rep. 2011;13(6):467–75. This is an excellent summary of the evidence supporting the role of the central and peripheral immune system in the development and recurrence of major depressive episodes and implications for novel treatments.
50. Moylan S, Eyre HA, Maes M, Baune BT, Jacka FN, Berk M. Exercising the worry away: how inflammation, oxidative and nitrogen stress mediates the beneficial effect of physical activity on anxiety disorder symptoms and behaviours. Neurosci Biobehav Rev. 2013;37(4):573–84.
51. Sylvia LG, Friedman ES, Kocsis JH, Bernstein EE, Brody BD, Kinrys G, et al. Association of exercise with quality of life and mood symptoms in a comparative effectiveness study of bipolar disorder. J Affect Disord. 2013;151(2):722–7.
52. Yirmiya R, Goshen I. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav Immun. 2011;25(2):181–213.
53. Stertz L, Magalhaes PV, Kapczinski F. Is bipolar disorder an inflammatory condition? The relevance of microglial activation. Curr Opin Psychiatry. 2013;26(1):19–26.
54. Gibney SM, Drexhage HA. Evidence for a dysregulated immune system in the etiology of psychiatric disorders. J Neuroimmune Pharmacol. 2013;8(4):900–20.
55. Kauer-Sant'Anna M, Kapczinski F, Andreazza AC, Bond DJ, Lam RW, Young LT, et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int J Neuropsychopharmacol. 2009;12(4):447–58.
56. Padmos RC, Hillegers MH, Knijff EM, Vonk R, Bouvy A, Staal FJ, et al. A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch Gen Psychiatry. 2008;65(4):395–407. This is an important paper describing novel gene expression findings in pro-inflammatory genes in both parents with bipolar disorder and their high-risk offspring.
57. Duffy A, Lewitzka U, Doucette S, Andreazza A, Grof P. Biological indicators of illness risk in offspring of bipolar parents: targeting the hypothalamic-pituitary-adrenal axis and immune system. Early Interv Psychiatry. 2012;6(2):128–37.
58. Hillegers MH, Reichart CG, Wals M, Verhulst FC, Ormel J, Nolen WA, et al. Signs of a higher prevalence of autoimmune thyroiditis in female offspring of bipolar parents. Eur Neuropsychopharmacol. 2007;17(6–7):394–9.
59. Ellenbogen MA, Hodgins S, Linnen AM, Ostiguy CS. Elevated daytime cortisol levels: a biomarker of subsequent major affective disorder? J Affect Disord. 2011;132(1–2):265–9.
60. Connor TJ, Leonard BE. Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci. 1998;62(7):583–606.
61. Deshauer D, Grof E, Alda M, Grof P. Patterns of DST positivity in remitted affective disorders. Biol Psychiatry. 1999;45(8):1023–9.
62. Maes M, Ringel K, Kubera M, Berk M, Rybakowski J. Increased autoimmune activity against 5-HT: a key component of depression that is associated with inflammation and activation of cell-mediated immunity, and with severity and staging of depression. J Affect Disord. 2012;136(3):386–92.
63. Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry. 2009;70(8):1078–90.
64. Zhang XY, Yao JK. Oxidative stress and therapeutic implications in psychiatric disorders. Prog Neuro-Psychopharmacol Biol Psychiatry. 2013;46:197–9.
65. Pandya CD, Howell KR, Pillai A. Antioxidants as potential therapeutics for neuropsychiatric disorders. Prog Neuro-Psychopharmacol Biol Psychiatry. 2013;46:214–23.
66. Magalhaes PV, Dean OM, Bush AI, Copolov DL, Malhi GS, Kohlmann K, et al. N-acetyl cysteine add-on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo-controlled trial. J Affect Disord. 2011;129(1–3):317–20.
67. Berk M, Dean O, Cotton SM, Gama CS, Kapczinski F, Fernandes BS, et al. The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial. J Affect Disord. 2011;135(1–3):389–94.
68. Gray KM, Carpenter MJ, Baker NL, DeSantis SM, Kryway E, Hartwell KJ, et al. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry. 2012;169(8):805–12.
69. Smesny S, Milleit B, Hipler UC, Milleit C, Schafer MR, Klier CM, et al. Omega-3 fatty acid supplementation changes intracellular phospholipase A activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis. Mol Psychiatry. 2013.
70. Bernardi JR, Ferreira CF, Senter G, Krolow R, de Aguiar BW, Portella AK, et al. Early life stress interacts with the diet deficiency of omega-3 fatty acids during the life course increasing the metabolic vulnerability in adult rats. PLoS One. 2013;8(4):e62031.
71. Andreazza AC, Kapczinski F, Kauer-Sant'Anna M, Walz JC, Bond DJ, Goncalves CA, et al. 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. J Psychiatry Neurosci. 2009;34(4):263–71.
72. Amminger GP, McGorry PD. Update on omega-3 polyunsaturated fatty acids in early-stage psychotic disorders. Neuropsychopharmacol: Off Publ Am Coll Neuropsychopharmacol. 2012;37(1):309–10.
73. Amminger GP, Schafer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2010;67(2):146–54. Important randomized placebo controlled 12-week trial of omega-3-fatty acids showing effectiveness in preventing conversion to psychosis in clinically high-risk individuals.
74. Mossaheb N, Schafer MR, Schlogelhofer M, Klier CM, Cotton SM, McGorry PD, et al. Effect of omega-3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective? Schizophr Res. 2013;148(1–3):163–7.
75. Strober M, Carlson G. Predictors of bipolar illness in adolescents with major depression: a follow-up investigation. Adolesc Psychiatry. 1982;10:299–319. An important sentinel paper identifying clinical predictors of bipolarity in depressed adolescents.
76. Strawn JR, Adler CM, McNamara RK, Welge JA, Bitter SM, Mills NP, et al. Antidepressant tolerability in anxious and depressed youth at high risk for bipolar disorder: a prospective naturalistic treatment study. Bipolar Disord. 2013.
77. Calkin C, Alda M. Beyond the guidelines for bipolar disorder: practical issues in long-term treatment with lithium. Can J Psychiatr Rev Can Psychiatr. 2012;57(7):437–45.
78. Grof P, Duffy A, Alda M, Hajek T. Lithium response across generations. Acta Psychiatr Scand. 2009;120(5):378–85.
79. Berghofer A, Alda M, Adli M, Baethge C, Bauer M, Bschor T, et al. Long-term effectiveness of lithium in bipolar disorder: a multicenter investigation of patients with typical and atypical features. J Clin Psychiatry. 2008;69(12):1860–8.
80. Calkin CV, Gardner DM, Ransom T, Alda M. The relationship between bipolar disorder and type 2 diabetes: more than just co-morbid disorders. Ann Med. 2013;45(2):171–81.
81. Gyulai L, Bauer M, Bauer MS, Garcia-Espana F, Cnaan A, Whybrow PC. Thyroid hypofunction in patients with rapid-cycling bipolar disorder after lithium challenge. Biol Psychiatry. 2003;53(10):899–905.